» Encouraging Results From Phase 2 Clinical Trial Of Bapineuzumab At International Conference On Alzheimer's Disease
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) are presenting detailed results from the companies’ 18-month Phase 2 study of bapineuzumab (AAB-001) in patients with mild to moderate…